myoma: Sonoguided-microwave Uterine Myoma

Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05129956
Collaborator
(none)
20
1
1
40.8
0.5

Study Details

Study Description

Brief Summary

This study mainly evaluates the resolution of uterine fibroids by microwave ablation. The medical equipment used is Ke Hui. "The Ampening ablation system is a percutaneous surgery. During laparoscopic surgery, it is directly ablated and soft, including problems that cannot be solved by partial or complete tissue ablation. "Hydrogen is used. If the expected range of ablation can be found, there is no need to wait for 3 to 6 months for ablation slowly like Haifu surgery. A fast, small, high-quality treatment that provides reference for medical treatment and helps doctors choose the most suitable treatment.

Condition or Disease Intervention/Treatment Phase
  • Device: "Covidien" Emprint Ablation System with Thermosphere Technology
N/A

Detailed Description

A collection of 20 women suffering from uterine fibroids were treated with microwave fibroids ablation for symptoms of uterine fibroids, and they could be discharged the next day or two days after surgery. Schedule return visits and routine blood tests according to clinical needs, and follow up with ultrasound and questionnaires during routine return visits (1, 3, and 6 months) after surgery. In the third month after surgery, there will be another imaging report. Magnetic resonance imaging and blood tests are used to compare the changes of patients' fibroids, their physiological recovery status, and the degree of improvement in their quality of life.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy Evaluation of Laparoscopic Sonoguided-microwave Uterine Myoma Ablation
Actual Study Start Date :
Aug 6, 2021
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: therapy group

Device: "Covidien" Emprint Ablation System with Thermosphere Technology
The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
Other Names:
  • "Covidien" Emprint Percutaneous Antenna with Thermosphere Technology
  • Outcome Measures

    Primary Outcome Measures

    1. Uterine myoma ablation [1 momth]

      The ablation range of fibroids can be reduced by 50%, measured by MRI cubic centimeter volume.

    2. Improve bleeding [3 momths]

      The hemoglobin changes before and 3 months after the operation are used to evaluate the improvement of patients' bleeding problems.

    Secondary Outcome Measures

    1. Reduce days in hospital [6 momths]

      Reduce the number of hospitalization days for patients to be less than or equal to 4 days.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Women who have reached the age of 20 and have not yet menopause.

    2. Myoma sizeā‰§4cm.

    3. Patients with submucosal fmyoma or intramural myoma of the uterus.

    Exclusion Criteria:
    1. Patients with subserosal myoma.

    2. Pregnant, breastfeeding or have menopause.

    3. Pelvic infections, vaginitis, cervicitis or endometritis and have not been cured.

    4. Malignant diseases of the cervix and uterus.

    5. Abnormal reports of clinical significance in Pap smear or thin-layer cell test.

    6. Abnormal blood coagulation function or liver and kidney function, with bleeding tendency.

    7. There is no safe puncture treatment route.

    8. Those who have installed intrauterine contraceptive device or Pacemaker.

    9. Those who cannot perform vaginal ultrasound, such as those who have no sexual experience and do not accept hymen repair.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) Kaohsiung Taiwan

    Sponsors and Collaborators

    • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Investigators

    • Principal Investigator: Cheng-Yu Long, Professor, Department of Obstetrics and Gynecology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kaohsiung Medical University Chung-Ho Memorial Hospital
    ClinicalTrials.gov Identifier:
    NCT05129956
    Other Study ID Numbers:
    • KMUHIRB-F(I)-20210131
    First Posted:
    Nov 22, 2021
    Last Update Posted:
    Nov 22, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Kaohsiung Medical University Chung-Ho Memorial Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 22, 2021